GSK had filed in patent application for fixed dose combination of Zidovudine/Lamivudine (AZT/3TC) in 1997. Click here to view the Complete Specifications of this Application.
Here is the Pre-Grant Opposition filed by PLHIV Community
Pre-Grant Opposition to AZT_3TC fixed dose combination Application No. 2044/CAL/1997
This opposition resulted in withdrawal of the application by GSK. Access here: Open Letter from GSK promising withdrawal of AZT/3TC FDC
Also view the Letter from Patent Office declaring the withdrawal of GSK application.
No comments:
Post a Comment